Recombinant humanized anti-HER2 antibody (herceptin(TM)) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts

Cancer Research

Volumn 58, Issue 13, 1998, Pages 2825-2831

  Baselga, Jose ^a,b   Norton, Larry ^a   Albanell, Joan ^b   Kim, Young Mee ^a   Mendelsohn, John ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MONOCLONAL ANTIBODY; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG EFFECT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE C ERB; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR REGRESSION; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM PROTEINS; PACLITAXEL; RECEPTOR, ERBB-2; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032127350     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hynes, N. E., and Stern, D. F. The biology of erB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta, 1198: 165-184, 1994.
2. Kraus, M. H., Issing, W., Miki, T., Popescu, N. C., and Aaronson, S. A. Isolation and characterization of ErbB3, a third member of the erbB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA, 90: 9193-9197, 1989.
3. erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA, 90: 1746-1750, 1993.
4. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
5. Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., Slamon, D. J., Phillips, R. N., Ross, J. S., Volman, S. R., and Flom, K. J. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncol., 15: 2894-2904, 1997.
6. Seshadri, R., Firgaira, F. A., Horsfall, D. J., McCaul, K., Setlur, V., and Kitchen, P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J. Clin. Oncol., 11: 1936-1942, 1993.
7. Hancock, M. C., Langton, B. C., Chan, T., Toy, P., Monahan, J. J., Mischak, R. P., and Shawver, L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res., 51: 4575-4580, 1991.
8. Drebin, J. A., Link, V. C., Stem, D. F., Weinberg, R. A., and Greene, M. I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell, 41: 695-706, 1985.
9. Stancovski, I., Hurwitz, E., Leitner, D., Ullrich, A., Yarden, Y., and Sela, M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the erbB-2 receptor on tumor growth. Proc. Natl. Acad. Sci. USA, 88: 8691-8695, 1991.
10. McKenzie, S. J., Marks, P. J., Lam, T., Morgan, J., Panicolli, D. L., Trimpe, K. L., and Camey, W. P. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene, 4: 543-548, 1989.
11. HER2 monoclonal antibodies. Cancer Immunol. Immunother., 37: 255-263, 1993.
12. Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., and Shepard, H. M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA, 89: 4285-4289, 1992.
13. HER2 monoclonal antibody has antiproliferative effects in vitro, and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol., 9: 1165-1172, 1989.
14. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14: 737-744, 1996.
15. Pietras, R. J., Fendly, B. M., Chazin, V. R., Pegram, M. D., Howell, S. D., and Slamon, D. J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene, 9: 1829-1838, 1994.
16. c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res., 54: 3758-3765, 1994.
17. Harris, J. R., Morrow, M., and Norton, L. Malignant tumors of the breast. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer, Principles and Practice of Oncology, Ed. 5, pp. 1557-1616. Philadelphia: Lippincott-Raven, 1997.
18. Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., Jr., and Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst., 85: 1327-1333, 1993.
19. Baselga, J., Norton, L., Coplan, K., Shalaby, R., and Mendelsohn, J. Antitumor activity of paclitaxel in combination with anti-growth factor receptor monoclonal antibodies in breast cancer xenografts. Proc. Am. Assoc. Cancer Res., 35: 2262, 1994.
20. Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., and Osborne, C. K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat., 24: 85-95, 1992.
21. Kumar, R., Shepard, H. M., and Mendelsohn, J. Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Mol. Cell. Biol., 11: 979-986, 1991.
22. Tokuda, Y., Ohnishi, Y., Shimamura, K., Iwasawa, M., Yoshimura, M., Ueyama, Y., Tamaoki, N., Tajima, T., and Mitomi, T. In vitro and in vivo anti-tumor effects of a humanised monoclonal antibody against c-erbB-2 product Br. J. Cancer, 73: 1362-1365, 1996.
23. Bos, M., Mendelsohn, J., Bowden, D., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., D'Andrea, G., Waksal, H., Norton, L., and Baselga, J. Phase I studies of anti-epidermal growth factor receptor (EGFR) chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors. Proc. Am. Soc. Clin. Oncol., 15. 443, 1996.
24. Ueno, N. T., Yu, D., and Hung, M. C. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene, 15: 953-960, 1997.
25. Zhang, L., and Hung, M-C. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene, 12: 571-576, 1996.
26. neu expressing non-small cell lung cancer cells. Cancer Res., 56: 1068-1074, 1996.
27. WAF1 and p53 requires c-raf-1. Cancer Res., 55: 4623-4626, 1995.
28. Pegram, M., Lipton, A., Pietras, R., Hayes, D., Weber, B., Baselga, J., Tripathy, D., Twaddell, T., Glaspy, J., and Slamon, D. Phase II study of intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody (rhuMAb HER-2) plus cisplatin in patients with HER-2/neu overexpressing metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 14: 1282, 1995.